AZNAstraZenecaRunning, no new patients
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Metastatic Castration-Sensitive Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,898 (final count)
- Started
- Nov 21, 2023
- Main results expected
- Sep 30, 2027
- Fully finished
- Apr 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression-Free Survival (rPFS)
Measured over: Up to approximately 50 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06120491 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC